Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Metabolic Instability of Peptide Therapeutics: Mechanisms, Analytical Strategies, and Design Solutions for Clinical Success

Metabolic instability is a key challenge in developing peptide therapeutics, and factors like rapid clearance and complex, multi-pathway biotransformation can further limit their effectiveness. Understanding and addressing these hurdles can unlock the full potential of peptide drugs, enabling them to reach challenging biological targets, support rational chemical design, and achieve clinical success. This webinar presents an integrated mechanism–analytics–design perspective to tackle these challenges and accelerate peptide drug discovery.

Accelerating Clinical Entry for Poorly Soluble Molecules: A Proven and Structured Roadmap

Poorly soluble molecules face unique challenges that can slow development and limit clinical success. Early formulation decisions are critical for determining bioavailability, in vivo exposure and the speed to IND submission and first-in-human studies. This webinar will show how tailored early-phase strategies, aligned with molecule properties and clinical stage, can overcome solubility, bioavailability limitations and related formulation challenges.

Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis

Potential to become a new modality in the treatment of ulcerative colitis offering prolonged remission without immune suppression

  • The study which compared MB310, a precision microbiome medicine, with placebo in 29 ulcerative colitis (UC) patients met its primary and secondary objectives to demonstrate safety, efficacy and engraftment:

    Efficacy:

BioTrinity 2026

BioTrinity is attended by an ever-evolving international audience of c.850 delegates, comprising a mix of academic entrepreneurs, early stage and emerging life sciences R&D companies, funders & investors, big pharma teams, charities & research bodies, government, regulatory bodies, along with professional services and expert supporters to the industry. 

This year’s event will feature a diverse global audience, international market showcases, dedicated investor networking, and presentations from the most promising life sciences companies.

Business Development Associate

About RxCelerate

The RxCelerate group provides a platform for out-sourced drug discovery and development services and has a client base ranging from virtual biotech companies to multinational pharmaceutical companies. We design and deliver complete drug development programmes and project management for our clients from inception through to Phase II clinical studies.

This role will support the growth and visibility of RxCelerate and its affiliates by contributing to both business development activities and marketing and communications initiatives.

The Role

Coulter Partners places renowned scientific leader Dr. Adam Davenport as CSO at Concept Life Sciences

LONDON, UK – February 11, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for Concept Life Sciences and is pleased to announce the placement of Dr. Adam Davenport as Chief Scientific Officer (CSO).

Logistics & Supply Chain Manager

Nuclera is a venture-backed biotech company headquartered in Cambridge, UK with significant operations in Boston, USA. Nuclera’s mission is to accelerate discovery by enabling rapid, easy access to functional proteins essential for drug discovery research. Our eProtein Discovery™ benchtop system accelerates protein expression and purification optimization in research labs.

Highly Efficient Kit Yields Significant Populations of Pure Myogenic Cells

Amsbio has introduced an expanded range of Skeletal Muscle Differentiation Kits designed to reproducibly convert pluripotent or embryonic stem cells into myoblasts with high regenerative potential.

Using a simple 3-step process of media changes and cell passaging – these advanced kits can typically achieve 70% MF20-positive myotubes. The highly efficient protocol employed by the kit does not require genetic intervention or cell sorting, thereby saving you valuable time.

Subscribe to